Enliven Therapeutics Appoints Kristine Ball to Board
Enliven Therapeutics has appointed Kristine Ball to its Board of Directors. The appointment comes as the company prepares to initiate a Phase 3 trial of its drug relcobatinib within the year.
Biopharmaceutical company Enliven Therapeutics announced on October 14, 2026, the appointment of Kristine Ball to its Board of Directors. Ball brings over 20 years of executive experience in the biopharmaceutical sector, with expertise in corporate strategy, finance, and commercial readiness.
Enliven CEO Rick Fair stated that Ball's experience in transitioning companies from clinical development to commercial operations will provide valuable perspective as Enliven prepares to initiate the pivotal Phase 3 trial of relcobatinib before year-end. The trial is focused on patients with chronic myeloid leukemia (CML).
Ball expressed a personal connection to the mission of treating CML and is eager to contribute to advancing relcobatinib through development and preparing Enliven for its next phase of growth. Her previous executive roles include CEO positions at Antiva Biosciences and Soteria Biotherapeutics, among others.
The company is currently preparing to initiate the pivotal Phase 3 ENABLE-2 trial for relcobatinib in previously treated CML patients before the end of 2026, following FDA alignment on the trial's final design.